Is psilocybin legal in Tennessee?

No. Psilocybin is a Schedule I controlled substance under federal law and is not legally available for clinical use in Tennessee. Outside of FDA-authorized research studies, there is no legal pathway to psilocybin therapy in this state. Music City Ketamine does not offer psilocybin in any form.

Which works better, ketamine or psilocybin?

There is no clean head-to-head answer. The two compounds have separate evidence bases built in different patient populations under different protocols. Ketamine has decades of clinical data and FDA-approved Spravato for treatment-resistant depression. Psilocybin trials at Johns Hopkins and Imperial College show promising depression results but remain investigational. Picking a winner from current data would overstate what the research can support.

Can I get psilocybin therapy in Oregon or Colorado?

Oregon and Colorado have created state-level frameworks that allow supervised psilocybin services within those states. Federal law still classifies psilocybin as Schedule I, so these programs exist in tension with federal scheduling. We share this for informational completeness only and do not recommend or facilitate access to those programs. Discuss any treatment decision with your own clinician.

Why is ketamine available but psilocybin is not?

Ketamine has been an FDA-approved anesthetic since 1970 and is a Schedule III controlled substance, which means physicians can prescribe it within established medical practice. Psychiatric and pain uses are off-label. Psilocybin is Schedule I, defined as having no accepted medical use, so it cannot be prescribed outside of FDA-authorized research even though it has Breakthrough Therapy designation for depression.

Could I have a similar experience with ketamine?

The two experiences are genuinely different. Ketamine produces a roughly 40 to 60 minute dissociative state at therapeutic doses. Psilocybin sessions in research trials run five to eight hours with intense visual and emotional content. Mechanism, duration, and subjective feel diverge meaningfully. Ketamine is not a substitute for psilocybin, and the choice is not interchangeable. It is a different tool with its own evidence base.

Ketamine vs Psilocybin: What the Evidence Actually Shows

Important note up front. Music City Ketamine does not offer psilocybin. We cannot offer psilocybin. Psilocybin remains a Schedule I controlled substance under federal law. This article is a research and education comparison only. If you are reading this hoping to access psilocybin therapy in Tennessee, the honest answer is that no legal pathway currently exists outside of FDA-authorized clinical trials.

Two different molecules, two different worlds

The psychedelic conversation has flattened two very different compounds into one category. Patients call us asking about “the ketamine and psilocybin treatments,” as if they are variations on the same therapy. They are not.

Ketamine is a dissociative anesthetic that has been in clinical use since 1970. It is a Schedule III controlled substance, which means physicians can prescribe it within established medical practice. Ketamine is FDA-approved as an anesthetic; its use for depression, PTSD, anxiety, and chronic pain is off-label. Spravato (esketamine), a related nasal-spray formulation, is FDA-approved for treatment-resistant depression and for major depressive disorder with acute suicidal ideation.

Psilocybin is the active compound in certain mushroom species. It is a Schedule I controlled substance, defined under the Controlled Substances Act as having no currently accepted medical use and a high potential for abuse. The FDA has granted Breakthrough Therapy designation to psilocybin for treatment-resistant depression, which speeds up regulatory review — but designation is not approval. As of this writing, psilocybin cannot be legally prescribed anywhere in the United States outside of FDA-authorized research.

Legal status: what you can actually access

This is the comparison that matters most for anyone weighing real options. The U.S. Drug Enforcement Administration confirms that psilocybin remains Schedule I federally. Tennessee follows federal scheduling, so there is no clinical psilocybin program available to a patient in Franklin, Nashville, or anywhere else in the state.

Two states — Oregon (under Measure 109) and Colorado (under Proposition 122) — have built state-licensed psilocybin service models. These programs allow supervised psilocybin use within those states under strict facilitator and facility licensing rules. They exist in legal tension with federal scheduling. Several other states have legislation in various stages, but nothing that creates clinical access in Tennessee.

Ketamine sits in a different regulatory place. As a Schedule III medication, it can be prescribed off-label by physicians for psychiatric and pain indications. We discuss the regulatory framing in more detail in our FDA and ketamine overview. Spravato is the FDA-approved version for depression; racemic IV ketamine is prescribed off-label for the same indication and several others. Both are real, available, and supervised.

So the practical comparison is not really “which one should I choose.” It is “one of these is available with a treating clinician today, and the other is not.”

How each one works in the brain

The two compounds reach altered states through completely different receptor systems, and the difference matters clinically.

Ketamine is an NMDA receptor antagonist. It binds to the channel inside the NMDA receptor and blocks glutamate signaling, then triggers a downstream cascade that increases brain-derived neurotrophic factor (BDNF) and synaptic plasticity. This glutamate-and-plasticity pathway is the mechanism most often cited in research on rapid antidepressant effects. We cover this in depth in how ketamine works.

Psilocybin is metabolized to psilocin, which is a partial agonist at the 5-HT2A serotonin receptor — particularly on layer V cortical pyramidal neurons. This is a different system entirely. Activation produces the perceptual and emotional content characteristic of psilocybin sessions and is associated with measurable changes in default mode network activity. Some preclinical work suggests psilocybin also promotes neuroplasticity, but through a serotonergic rather than glutamatergic route.

In short: NMDA antagonist vs 5-HT2A agonist. Glutamate vs serotonin. Different molecular biology, different subjective experience, different research literature. The brain research on ketamine is its own body of work, separate from the psilocybin trials.

What the strongest psilocybin trials show

The two studies most frequently cited as anchoring the modern psilocybin-for-depression evidence base are both worth reading carefully.

The Johns Hopkins trial, Davis and colleagues (2021), was published in JAMA Psychiatry. It was a randomized waitlist-controlled study of psilocybin-assisted therapy in 24 adults with major depressive disorder. Patients receiving immediate treatment showed large reductions in depression scores at four and eight weeks compared with the delayed-treatment control group. The effect sizes were notable, and the response was sustained at follow-up. This is a small trial, but the magnitude of change attracted significant clinical attention.

The Imperial College trial, Carhart-Harris and colleagues (2021), was published in the New England Journal of Medicine. It was a double-blind comparison of psilocybin against escitalopram (a standard SSRI) in 59 patients with moderate-to-severe major depressive disorder. On the trial’s primary depression-rating endpoint, the two arms produced statistically comparable results. On several secondary measures — including patient-reported wellbeing and remission rates — psilocybin showed favorable patterns. The trial was not powered to declare superiority, and the authors were careful in their conclusions.

A 2022 follow-up, also led by Davis and colleagues, reported sustained improvements in a subset of patients at twelve months. Other research groups have published work on psilocybin for substance use disorders, end-of-life anxiety, and treatment-resistant depression. The evidence is consistently interesting. It is also still small in total participant numbers, conducted under highly structured research conditions with substantial preparatory and integration psychotherapy, and has not yet produced FDA approval.

Promising early-phase data is not the same as clinical availability. The strongest psilocybin trials show meaningful signal for depression, but the regulatory and access reality is that this remains a research compound in the United States. — Synthesis of Davis et al., JAMA Psychiatry 2021; Carhart-Harris et al., NEJM 2021

What the strongest ketamine evidence shows

The ketamine evidence base is older, larger, and more clinically translated. Randomized controlled trials going back to the early 2000s, including landmark NIH work by Zarate and colleagues, have shown rapid reductions in depression scores within hours of a single subanesthetic IV dose. Subsequent trials confirmed the pattern across treatment-resistant depression and bipolar depression. Meta-analyses through the 2020s consistently support a meaningful, if often time-limited, antidepressant effect from racemic IV ketamine.

On the regulatory side, the U.S. Food and Drug Administration approved Spravato (esketamine) nasal spray in 2019 for treatment-resistant depression, and expanded the indication in 2020 to include depression with acute suicidal ideation. Racemic IV ketamine, the form used at most ketamine infusion clinics, is not FDA-approved for psychiatric indications and is prescribed off-label. We compare the two formulations in detail in ketamine vs Spravato.

Two things follow. First, ketamine has FDA-recognized utility in depression in the form of Spravato — a regulatory milestone psilocybin has not yet reached. Second, the broader clinical practice of IV ketamine for depression and related conditions is built on real peer-reviewed evidence, but operates off-label and should be discussed honestly with patients in those terms.

Session experience: a 40-minute infusion vs a 6-hour journey

The subjective experience of these two compounds is meaningfully different, and that difference shapes how each session is structured.

A standard IV ketamine infusion at a clinic like ours runs about 40 minutes. The dissociative effects ramp up within the first several minutes, hold a plateau, and resolve within roughly 15 to 30 minutes after the infusion ends. Patients are typically lucid and conversational again before they leave the clinic, though they need a driver. We describe the full arc in what to expect at your first infusion.

Psilocybin sessions in research settings unfold over five to eight hours from dose administration to return to baseline. The acute effects build for roughly two hours, peak across the middle of the session, and gradually subside. Trial protocols include extensive pre-session preparation with trained therapists and post-session integration sessions in the days following. The model is much closer to a single high-intensity intervention with substantial psychotherapeutic scaffolding than to a series of brief medical procedures.

Neither model is inherently better. They are matched to the pharmacology of each compound. Ketamine’s shorter duration makes repeated sessions practical, which is how our induction protocols are structured. Psilocybin’s longer duration means trials usually involve only one or two large dosing sessions across an entire treatment course.

What this means for someone in Tennessee right now

If you are weighing options today, the choice in Tennessee is not really between ketamine and psilocybin. It is between ketamine and not-yet. Psilocybin therapy is not legally available here. We are not going to walk you through workarounds. We will tell you honestly that the research is interesting, that several trials look promising, and that none of it changes the legal status this year.

For ketamine specifically: it is FDA-approved as an anesthetic, and its use for depression, anxiety, PTSD, and chronic pain is off-label. The clinical evidence supports its use in carefully selected patients who have not adequately responded to standard treatments. We are careful with our language and avoid overpromising. Research suggests it can produce meaningful and sometimes rapid improvement for patients in the right clinical context, with real but typically mild and transient side effects.

At Music City Ketamine, every infusion is administered by Marla Peterson, CRNA, with anesthesia-level monitoring and a CRNA on-site throughout the session. The clinical standard, the equipment, and the supervision are the same we used in the operating room. We do not stop, start, or change your other medications — that conversation belongs with your prescribing provider. Sessions are $475 each; the broader cost picture is in our ketamine therapy cost overview.

If a future arrives where psilocybin becomes FDA-approved and clinically available in Tennessee, that will be a different conversation. For now, ketamine is the option that exists with full medical supervision and a real evidence base behind it.